What are the latest strategies to overcome immune tolerance?
Registration for this session is additional to the congress registration fee and is €122 on site, €110 standard.
Aims : Immunotherapy has already developed to a new life-prolonging therapeutic backbone in advanced non-small cell lung cancer with significantly life-prolonging checkpoint-inhibitors available not only for second line but also first line therapy in routine care. The aim of this session is to provide a most current and comprehensive update as well as a future perspective on the advanced use of established and new immunotherapeutic drugs in lung cancer. The emphasis is on the combination of immunotherapeutic drugs with present treatment modalities such as other systemic therapies or radiotherapy since these seem to bear the potential to booster immunotherapy.